N-(4-乙氧苯基)-N-甲基乙酰胺 | 7298-73-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-(4-乙氧苯基)-N-甲基乙酰胺
• 中文别名: 4-乙氧基甲基乙酰苯胺；4-乙氧基-N-甲基乙酰苯胺
• 英文名称: acetic acid-(N-methyl-p-phenetidide)
• 英文别名: Essigsaeure-(N-methyl-p-phenetidid)；4-(Acetylmethylamino)-phenol-aethylaether；N-Methyl-(acet-p-phenetidid)；N-Methyl-phenacetin；4'-ethoxy-N-methylacetanilide；N-Acetyl-N-methyl-4-aethoxy-anilin；N-(4-Ethoxyphenyl)-N-methylacetamide
• CAS: 7298-73-9
• 化学式: C₁₁H₁₅NO₂
• 分子量: 193.246
• InChiKey: LLYKXHAEYFJRQZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  2

制备方法与用途

化学性质：液体，沸点为120-122℃（13.6Pa）。

用途：作为催醒宁的中间体。

生产方法：通过在碘化四丁基铵参与下，使用硫酸二甲酯对对乙氧基乙酰苯胺进行甲基化反应制得该产品。

反应信息

• 作为反应物：
  描述：

  N-(4-乙氧苯基)-N-甲基乙酰胺 生成 N-methyl-p-phenetidine
  参考文献：
  名称：

  JI, QINGE, PHARM. IND., 1983, N 8, 7-8

  摘要：

  DOI：
• 作为产物：
  描述：

  对乙氧基苯胺 在 (2S)-N-methyl-1-phenylpropan-2-amine hydrate 、 sodium 、 xylene 作用下， 生成 N-(4-乙氧苯基)-N-甲基乙酰胺
  参考文献：
  名称：

  Hinsberg, Justus Liebigs Annalen der Chemie, 1899, vol. 305, p. 287

  摘要：

  DOI：

文献信息

• REMEDIES FOR NEUROPATHIC PAIN
  申请人：MOCHIDA PHARMACEUTICAL CO., LTD.

  公开号：EP1182193A1

  公开（公告）日：2002-02-27

  The present invention relates to a compound represented by Formula (I) below: (wherein A represents, for example, phenyl group substituted by R1 and R2, or an unsubstituted furyl group or an unsubstitued thienyl group; R1 represents, for example, hydrogen atom, fluorine atom, chlorine atom, trifluoromethyl group, nitro group, cyano group or methyl group while R2 represents, for example, hydrogen atom; R3 represents, for example, hydrogen atom or methyl group; R4 represents, for example, hydrogen atom or methyl group; R5 represents ethoxy group or isopropoxy group; X represents group: -CH(OH)- or methylene group; and Z represents, for example, a single bond or methylene group unsubstituted or substituted by hydroxyl group), and its salts, and medicinal compositions containing, as their active ingredient, the above compound or its salts. The compound of this invention, which is orally applicable, is highly effective for treating neuroapthic pain while presenting with fewer side-effects than do the conventional analgesics.

  本发明涉及一种化合物，其由以下通式(I)表示：(其中A代表例如被R1和R2取代的苯基，或未被取代的呋喃基或未被取代的噻吩基；R1代表例如氢原子、氟原子、氯原子、三氟甲基、硝基、氰基或甲基，而R2代表例如氢原子；R3代表例如氢原子或甲基；R4代表例如氢原子或甲基；R5代表乙氧基或异丙氧基；X代表基团：-CH(OH)-或亚甲基；Z代表例如单键或未被取代或被羟基取代的亚甲基)，及其盐，以及含有上述化合物或其盐作为活性成分的药物组合物。本发明的化合物可经口给药，对治疗神经痛性疼痛具有高度有效性，且相比传统镇痛药副作用更少。
• Agents for treating neuropathic pain
  申请人：MOCHIDA PHARMACEUTICAL CO., LTD.

  公开号：US20020049229A1

  公开（公告）日：2002-04-25

  The present invention relates to a compound represented by Formula (I) below: 1 (wherein A represents, for example, phenyl group substituted by R 1 and R 2 , or an unsubstituted furyl group or an unsubstitued thienyl group; R 1 represents, for example, hydrogen atom, fluorine atom, chlorine atom, trifluoromethyl group, nitro group, cyano group or methyl group while R 2 represents, for example, hydrogen atom; R 3 represents, for example, hydrogen atom or methyl group; R 4 represents, for example, hydrogen atom or methyl group; R 5 represents ethoxy group or isopropoxy group; X represents group: —CH(OH)— or methylene group; and Z represents, for example, a single bond or methylene group unsubstituted or substituted by hydroxyl group), and its salts, and medicinal compositions containing, as their active ingredient, the above compound or its salts. The compound of this invention, which is orally applicable, is highly effective for treating neuroapthic pain while presenting with fewer side-effects than do the conventional analgesics.

  本发明涉及一种化合物，其由下面的式(I)表示：1（其中A表示例如由R1和R2取代的苯基，或未取代的呋喃基或未取代的噻吩基；R1表示例如氢原子、氟原子、氯原子、三氟甲基、硝基、氰基或甲基，而R2表示例如氢原子；R3表示例如氢原子或甲基；R4表示例如氢原子或甲基；R5表示乙氧基或异丙氧基；X表示基团：—CH(OH)—或亚甲基；Z表示例如单键或未取代或由羟基取代的亚甲基），及其盐，以及含有上述化合物或其盐作为活性成分的药物组合物。本发明的化合物可口服使用，在治疗神经性疼痛方面具有高效率，同时相比传统镇痛药副作用更少。
• Anodic oxidation of carboxamides. Part 3. The mechanism of anodic cyclization of N-methylcarbanilides
  作者：Hidenobu Ohmori、Chihiro Ueda、Yasuhiro Nobusue、Naoko Saitou、Tomoko Yokota、Masaichiro Masui

  DOI：10.1039/p29810001599

  日期：——

  Anodic oxidation in methanol of N-methylcarbanilides with an alkoxy-group para to the nitrogen atom (I) gives the intramolecular cyclization products, N-methylbenzoxazolium perchlorates: no cyclization product is obtained in the electrolysis of the anilides in acetonitrile. The process of cyclization was investigated by cyclic voltammetry, controlled potential electrolysis, and open circuit relaxation

  在甲醇阳极氧化Ñ与烷氧基的基团-methylcarbanilides对位的氮原子（I）给出的分子内环化的产品，Ñ -methylbenzoxazolium高氯酸盐：在乙腈中的N-酰苯胺的电解没有获得环化产物。通过循环伏安法，受控电势电解和使用光学透明玻璃碳电极的开路弛豫实验研究了环化过程。在甲醇中4'-甲氧基-N-甲基苯甲腈（Ib–d）的光谱电化学实验中，已证明了亚稳中间体的积累。讨论了可能形成苯并恶唑盐的反应顺序。
• 4-hydroxypiperidine derivatives having antiarrhythmic activity
  申请人：Mochida Pharmaceutical Co., Ltd.

  公开号：US20020188006A1

  公开（公告）日：2002-12-12

  The present invention relates to a compound represented by the following formula (I) or a salt thereof, or a pharmaceutical composition containing the compound as an effective ingredient: 1 (wherein A represents, for example, phenyl group substituted with R 1 and R 2 or unsubstituted thienyl group; R 1 and R 2 each independently represent, for example, hydrogen atom, halogen atom or lower alkoxycarbonyl group; R 3 represents, for example, hydrogen atom; R 4 represents, For example, lower alkyl group; R 5 represents, for example, lower alkoxy group; R 6 represents, for example, hydrogen atom; R 7 and R 8 each represent, for example, hydrogen atom, respectively; X represents, for example, a single bond; Y represents, for example, methylene group or benzylidene group substituted with R 1 ; and Z represents, for example, methylene group.) The compounds according to the present invention that do not suppress the transient sodium current of the cardiac muscle and do not manifest proarrhythimic activity is useful as a therapeutic agent for preventing and/or treating arrhythimia and for preventing sudden death.

  本发明涉及以下式(I)所表示的化合物或其盐，或含有该化合物作为有效成分的药物组合物：1（其中A代表例如被R1和R2取代的苯基或未被取代的噻吩基；R1和R2各自独立地代表例如氢原子、卤素原子或低碳酸酯基；R3代表例如氢原子；R4代表例如低烷基基团；R5代表例如低烷氧基团；R6代表例如氢原子；R7和R8各自代表例如氢原子；X代表例如单键；Y代表例如被R1取代的亚甲基基团或苄亚甲基基团；以及Z代表例如亚甲基基团。）本发明的化合物不抑制心肌瞬时钠电流，也不表现出致心律失常活性，因此可用作预防和/或治疗心律不齐和预防猝死的治疗剂。
• BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME
  申请人：Coferon, Inc.

  公开号：US20140243286A1

  公开（公告）日：2014-08-28

  Described herein are monomers capable of forming a biologically useful multimer when in contact with one, two, three or more other monomers in an aqueous media. In one aspect, such monomers may be capable of binding to another monomer in an aqueous media (e.g. in vivo) to form a multimer (e.g. a dimer). Contemplated monomers may include a ligand moiety, a linker element, and a connector element that joins the ligand moiety and the linker element. In an aqueous media, such contemplated monomers may join together via each linker element and may thus be capable of modulating one or more biomolecules substantially simultaneously, e.g., modulate two or more binding domains on a protein or on different proteins.

  本文介绍了一种单体，当在水介质中与一个、两个、三个或更多其他单体接触时，能够形成生物上有用的多聚体。在其中一方面，这种单体可以在水介质中（例如在体内）与另一个单体结合形成多聚体（例如二聚体）。考虑到的单体可能包括配体基团、连接元素和连接配体基团和连接元素的连接元素。在水介质中，这些考虑到的单体可以通过每个连接元素连接在一起，因此可以同时调节一个或多个生物分子，例如调节蛋白质或不同蛋白质上的两个或更多结合结构域。